MajesTEC-9 Results at ASCO 2026: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
oncodaily - At ASCO 2026, results from MajesTEC-9 (NCT05572515), the first phase 3 study of teclistamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, […]
AI Summary: Teclistamab monotherapy demonstrated superior progression-free survival and response rates versus pomalidomide‑based (PVd) and carfilzomib‑based (Kd) regimens in earlier-line relapsed/refractory multiple myeloma, showing durable remissions at 18 months. The data suggest a shift toward bispecific antibody therapy earlier in the treatment sequence for many patients.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Common asthma drug may overcome immunotherapy resistance in cancers / 11 days
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 5 wks
James P. Allison wins AACR lifetime achievement award / 7 wks
Metabolic enzyme linked to immunotherapy benefit; routing metabolites may boost response / 1 month
Atezolizumab plus FOLFOX improves DFS in Stage III dMMR colon cancer / 1 month
AstraZeneca’s in‑vivo CAR‑T yields early responses but raises safety questions / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicaid, Medicare Advantage (not listed), Neuroscience, Vaccine Safety and look for the RSS link.
StackHealth Time Machine